Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.

Bryan King | Thomas Trimarchi | Linsey Reavie | Luyao Xu | Jasper Mullenders | Panagiotis Ntziachristos | Beatriz Aranda-Orgilles | Arianne Perez-Garcia | Junwei Shi | Christopher Vakoc | Peter Sandy | Steven S Shen | Adolfo Ferrando | Iannis Aifantis
Cell | 2013

Sequencing efforts led to the identification of somatic mutations that could affect the self-renewal and differentiation of cancer-initiating cells. One such recurrent mutation targets the binding pocket of the ubiquitin ligase Fbxw7. Missense FBXW7 mutations are prevalent in various tumors, including T cell acute lymphoblastic leukemia (T-ALL). To study the effects of such lesions, we generated animals carrying regulatable Fbxw7 mutant alleles. Here, we show that these mutations specifically bolster cancer-initiating cell activity in collaboration with Notch1 oncogenes but spare normal hematopoietic stem cell function. We were also able to show that FBXW7 mutations specifically affect the ubiquitylation and half-life of c-Myc protein, a key T-ALL oncogene. Using animals carrying c-Myc fusion alleles, we connected Fbxw7 function to c-Myc abundance and correlated c-Myc expression to leukemia-initiating activity. Finally, we demonstrated that small-molecule-mediated suppression of MYC activity leads to T-ALL remission, suggesting an effective therapeutic strategy.

Pubmed ID: 23791182

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA173636
  • Agency: NCI NIH HHS, United States
    Id: P30 CA016087
  • Agency: NCI NIH HHS, United States
    Id: R01 CA133379
  • Agency: NCI NIH HHS, United States
    Id: 5P30CA16087-31
  • Agency: NIGMS NIH HHS, United States
    Id: 1R01GM088847
  • Agency: NCI NIH HHS, United States
    Id: P30CA016087-30
  • Agency: NCI NIH HHS, United States
    Id: R01 CA149655
  • Agency: NCI NIH HHS, United States
    Id: R01 CA105129
  • Agency: NCI NIH HHS, United States
    Id: 5R01CA173636
  • Agency: NCI NIH HHS, United States
    Id: 1R01CA105129
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM088847
  • Agency: NCI NIH HHS, United States
    Id: 1R01CA133379
  • Agency: NCI NIH HHS, United States
    Id: 1R01CA149655

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.